$10.350
+0.030 (+0.29%)收盤時
RCEL 資訊
RCEL 事件
AVITA Q2 Revenue at $21.7M, Below Consensus
Reports Q2 revenue $21.7M, consensus $28.7M. The company said, "We delivered a strong second quarter, with revenue growing 18% year-over-year and 13% sequentially. As AVITA continues to expand utilization in the U.S. and build its presence in key international markets, our results reflect the strength of both our acute wound care portfolio and our commercial execution, led by RECELL and supported by Cohealyx and PermeaDerm. We are delivering this growth while maintaining a high gross margin and disciplined operating expenses and use of cash. Together, these results demonstrate that AVITA has evolved into a business capable of sustained, durable growth, giving us the confidence to raise our full-year revenue guidance and to announce our expectation to reach cash flow breakeven in the fourth quarter."
AVITA Medical Presents First Clinical Data of RECELL GO in the UK
AVITA Medical announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K. The presentation, titled "First U.K. Clinical Experience of RECELL GO, an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series," reports outcomes from 17 patients treated at Stoke Mandeville Hospital, one of the U.K.'s leading specialist burn units. Investigators evaluated the use of RECELL GO, AVITA Medical's next-generation automated system for preparing RECELL Spray-On Skin Cells, across a range of burn and reconstructive procedures. In the U.K. case series, all patients successfully received RECELL Spray-On Skin Cells prepared using RECELL GO, either alone or in conjunction with meshed split-thickness skin grafts. Investigators reported uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. The authors also noted workflow benefits, including reduced procedural variability, improved consistency of cell preparation, and greater operating room efficiency.
FY26 Revenue Expected to Reach $80M-$85M
FY26 revenue is expected to be in the range of $80M-$85M, representing growth of approximately 12%-19% compared to FY25 revenue.
AVITA Reports Q1 Revenue of $19.3M, Below Expectations
Reports Q1 revenue $19.3M, consensus $24.65M. Cary Vance, CEO, commented: "Since November, we've stabilized the business, improved how we operate, and delivered a solid start to 2026. With sequential revenue growth and improving ordering patterns across the portfolio, we are focused on delivering sustained performance as we move through the year. At April's American Burn Association annual meeting, it was exciting to see how our products, RECELL, Cohealyx and PermeaDerm, are delivering meaningful outcomes for clinicians and their patients. I am incredibly proud and excited to lead AVITA as we continue to build towards the future of wound care."
Avita Medical Appoints Cary Vance as CEO
Avita Medical announced that its board of directors has appointed Cary Vance as president and CEO, effective immediately. The board of directors has also appointed Jan Stern Reed as its chair, effective immediately. Vance, who has served as interim CEO since October 2025, will continue to serve on the board as an executive member. Vance has served on the Avita Medical board of directors since 2023 and was previously appointed chairman in 2025.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。